Activity Overview | Enhancing Clinical Outcomes in Hepatocellular Carcinoma: A Multidisciplinary Expert Practice Meeting will discuss emerging data and provide updates on current standards of care for all stages of HCC. During this meeting, leaders in the field will discuss, in an interactive format, clinical issues encountered daily by practicing physicians. |
 Agenda |
| 7.00 AM |
|
Registration and breakfast
|
| 8.00 AM |
|
Welcome, introduction, and demographics
Ghassan Abou-Alfa, MD
Alan P. Venook, MD
|
| 8.15 AM |
|
Pattern of practice question
|
| 8.20 AM |
|
Why is the incidence of HCC rising?
Jorge A. Marrero, MD
|
| 8.40 AM |
|
Pattern of practice question
|
| 8.45 AM |
|
Multidisciplinary management of HCC: An evolving story
Massimo Colombo, MD
|
| 9.05 AM |
|
Pattern of practice question
|
| 9.10 AM |
|
Molecular classification of HCC: Importance of translational research
Yujin Hoshida, MD, PhD
|
| 9.30 AM |
|
Pattern of practice question
|
| 9.35 AM |
|
Keynote Lecture: Targeting signaling pathways in HCC: Novel molecular targeted therapies on the horizon
Richard S. Finn, MD
|
| 10.00 AM |
|
Break
|
| 10.20 AM |
|
Case #1: Advanced unresectable HCC: A multidisciplinary clinicopathologic conference
Ghassan Abou-Alfa, MD, and faculty panel
|
| 11.00 AM |
|
Case #2: Treatment options for a patient with pretreated HCC: A multidisciplinary clinicopathologic conference
Alan P. Venook, MD, and faculty panel
|
| 11.40 AM |
|
Roundtable discussion
All faculty
|
| 12.30 PM |
|
Concluding remarks followed by lunch |
|
Faculty |
Co-Chairs
Ghassan Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Alan P. Venook, MD
University of California, San Francisco
San Francisco, California, United States
Faculty
Massimo Colombo, MD
University of Milan
Milan, Italy
Richard S. Finn, MD
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California, United States
Yujin Hoshida, MD, PhD
Broad Institute
Massachusetts Institute of Technology
and Harvard University
Cambridge, Massachusetts, United States
Jorge A. Marrero, MD, MS
University of Michigan
Ann Arbor, Michigan, United States
|
Target Audience | This educational activity is specifically designed for medical oncologists, hepatologists, surgical oncologists, radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with hepatocellular carcinoma. |
Educational Objectives | Upon completion of this educational activity, participants should be able to:
- Discuss the epidemiology and risk factors for hepatocellular carcinoma (HCC), and discuss strategies for screening and surveillance
- Examine the current understanding of HCC tumor biology with regard to gene profiling, molecular targets, biomarkers, and risk-assessment strategies
- Describe current standards of care and recent advances in the treatment of advanced unresectable HCC, including the role of targeted therapies, patient selection, and appropriate response-monitoring strategies
- Discuss the efficacy and safety of treatment options for patients with metastatic HCC beyond first-line therapy, including chemotherapy and novel targeted agents
- Identify the importance of a multidisciplinary approach in the treatment of patients with HCC
|
Disclosure of Conflicts of Interest | prIME Oncology assess conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. |
Disclosure of Unlabeled Use of Agents | This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food & Drug Administration or the European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
Location | The Fairmont San Francisco
950 Mason Street
San Francisco, CA 94108
415.772.5000 |
Sponsorship | This activity is sponsored by prIME Oncology.
 |
Continuing Education |
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this live educational activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Support | Support for this educational activity has been provided by:
|
|
